EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction

Tzu-Fei Wang, Alok A Khorana, Giancarlo Agnelli, Dan Bloomfield, Marc P Bonaca, Harry R Büller, Jean M Connors, Shinya Goto, Zhi-Cheng Jing, Ajay K Kakkar, Yasser Khder, Gary E Raskob und 4 weitere

The Oncologist · 05.07.2023 · 28 (7) · 555-564

DOI: 10.1093/oncolo/oyad116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 12.05.2023. Verfasst von Tzu-Fei Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, Canada. Hauptthemen laut MEDLINE: Venous Thromboembolism, Thrombosis, Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-associated thrombosis, with the incidence rising over the years, is associated with significant morbidity and mortality in patients with cancer. Recent advances in the treatment of cancer-associated venous thromboembolism (VTE) include the introduction of direct oral anticoagulants (DOACs), which provide a more convenient and effective option than low-molecular-weight heparin (LMWH). Nonetheless, important unmet needs remain including an increased risk of bleeding in certain patient subgroups such as those with gastroesophageal cancer, concerns about drug-drug interactions, and management of patients with severe renal impairment. Although DOACs are more convenient than LMWH, persistence can decline over time. Factor XI inhibitors have potential safety advantages over DOACs because factor XI appears to be essential for thrombosis but not hemostasis. In phase II trials, some factor XI inhibitors were superior to enoxaparin for the prevention of VTE after knee replacement surgery without increasing the risk of bleeding. Ongoing trials are assessing the efficacy and safety of factor XI inhibitors for the treatment of cancer-associated VTE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismThrombosisNeoplasmsHumansHeparin, Low-Molecular-WeightAnticoagulantsFactor XIHemorrhage

Stichwörter der Autor:innen

anticoagulantsfactor XIfactor XIa inhibitorsheparinlow-molecular-weight heparinneoplasmsvenous thromboembolism

Substanzen

Heparin, Low-Molecular-WeightAnticoagulantsFactor XI

Autor:innen und Institutionen

  • Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, Canada.
  • Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Internal Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy.
  • Anthos Therapeutics, Cambridge, MA, USA.
  • Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA.
  • CPC Clinical Research, Aurora, CO, USA.

ORCID-Profile: Marc Carrier

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • Chinese Academy of Medical Sciences

Zitieren

APA

Wang, T. F., Khorana, A. A., Agnelli, G., Bloomfield, D., Bonaca, M. P., Büller, H. R., Connors, J. M., Goto, S., Jing, Z. C., Kakkar, A. K., Khder, Y., Raskob, G. E., Soff, G. A., Verhamme, P., Weitz, J. I., & Carrier, M. (2023). Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. The Oncologist, 28(7), 555-564. https://doi.org/10.1093/oncolo/oyad116

Vancouver

Wang TF, Khorana AA, Agnelli G, Bloomfield D, Bonaca MP, Büller HR, et al. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. The Oncologist. 2023;28(7):555-564. doi:10.1093/oncolo/oyad116

BibTeX
@article{Wang2023,
  author = {Wang, Tzu-Fei and Khorana, Alok A and Agnelli, Giancarlo and Bloomfield, Dan and Bonaca, Marc P and Büller, Harry R and Connors, Jean M and Goto, Shinya and Jing, Zhi-Cheng and Kakkar, Ajay K and Khder, Yasser and Raskob, Gary E and Soff, Gerald A and Verhamme, Peter and Weitz, Jeffrey I and Carrier, Marc},
  title = {Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {7},
  pages = {555--564},
  doi = {10.1093/oncolo/oyad116}
}
Kostenlos starten →